Will resistance in fungi emerge on a scale similar to that seen in bacteria?

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
Herbert Hof

Abstract

Growing numbers of patients receive azoles as prophylaxis or treatment for invasive fungal infections, begging the question of whether emergence of resistance will occur, as has been seen with bacteria. This review examines resistance pathways shared by bacteria and fungi, including alteration and overproduction of drug targets, changes in biosynthetic pathways, and enhanced drug efflux, and assesses whether such commonalities predict increased resistance to azoles. Important differences exist between the two kingdoms, including little, if any, horizontal transfer of extrachromosomal material across fungal species and a longer fungal generation time, thereby slowing vertical transfer of mutant traits. Further, no enzymatic modulation or inactivation of azoles has been reported in fungi. The newer broad-spectrum azoles posaconazole and voriconazole are active against the vast majority of yeasts and moulds and are likely to prevent the emergence of inherently resistant strains. Therefore, the likelihood for an explosion of fungal resistance is relatively low.

References

Jan 1, 1987·Critical Reviews in Microbiology·H Vanden BosscheP Marichal
Jan 1, 1995·Antimicrobial Agents and Chemotherapy·J H RexM A Pfaller
Feb 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S ReddingM Pfaller
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·P MarichalP Mose-Larsen
Nov 14, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K A MarrR A Bowden
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D W Denning
Aug 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C ViscoliF Meunier
Dec 11, 1999·Mycoses·F Schauer, R Hanschke
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J LinS M Teutsch
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·H Hof
Oct 30, 2001·FEMS Microbiology Letters·L E Cowen
Jan 25, 2002·The New England Journal of Medicine·Thomas J WalshUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group
Mar 21, 2002·The Lancet Infectious Diseases·Dominique Sanglard, Frank C Odds
Jun 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Leah E CowenJames B Anderson
Aug 6, 2002·Current Opinion in Microbiology·Dominique Sanglard
Oct 18, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sofia Perea, Thomas F Patterson
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Sep 17, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·William J Steinbach, David A Stevens
Dec 6, 2003·The Journal of Antimicrobial Chemotherapy·Xin LiPaul M McNicholas
Dec 10, 2003·Journal of Clinical Microbiology·Kevin C HazenUNKNOWN Global Antifungal Surveillance Group
Dec 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marcus J ZervosTeresa J Lubowski
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·Sophie BrunJean-Philippe Bouchara
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Nov 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R Wingard
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Alfonso-Javier Carrillo-MuñozPatricia Santos

❮ Previous
Next ❯

Citations

Dec 22, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dariusz T MlynarczykTomasz Goslinski
Oct 11, 2012·ACS Medicinal Chemistry Letters·Sheo B SinghJanet C Onishi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved